MinireviewRevised consensus statement on the preventive and symptomatic care of patients with leukodystrophies

- Leukodystrophies are diverse group of genetic disorders that result in the disruption or destruction of central myelination.
- While few leukodystrophies have curative treatments, lack of cures should not mean lack of care.
- A holistic approach focused on common complications can improve quality of life and can complement efforts directed at curative therapies.

Leukodystrophies are a broad class of genetic disorders that result in disruption or destruction of central myelination. Although the mechanisms underlying these disorders are heterogeneous, there are many common symptoms that affect patients irrespective of the genetic diagnosis. The comfort and quality of life of these children is a primary goal that can complement efforts directed at curative therapies. Contained within this report is a systems-based approach to management of complications that result from leukodystrophies. We discuss the initial evaluation, identification of common medical issues, and management options to establish a comprehensive, standardized care approach. We will also address clinical topics relevant to select leukodystrophies, such as gallbladder pathology and adrenal insufficiency. The recommendations within this review rely on existing studies and consensus opinions and underscore the need for future research on evidence-based outcomes to better treat the manifestations of this unique set of genetic disorders.